Cybin Inc. (NYSEAMERICAN:CYBN – Get Free Report) shares shot up 2.3% during trading on Thursday . The stock traded as high as $0.27 and last traded at $0.27. 2,661,981 shares were traded during mid-day trading, a decline of 44% from the average session volume of 4,717,433 shares. The stock had previously closed at $0.26.
Cybin Stock Down 2.3 %
The stock has a market cap of $108.75 million, a price-to-earnings ratio of -1.26 and a beta of 0.50.
Cybin (NYSEAMERICAN:CYBN – Get Free Report) last issued its quarterly earnings results on Wednesday, June 26th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Equities analysts predict that Cybin Inc. will post -0.22 EPS for the current year.
Institutional Investors Weigh In On Cybin
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 8/5 – 8/9
- CD Calculator: Certificate of Deposit Calculator
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.